Risk of major bleeding in elderly patients with atrial fibrillation on direct oral anticoagulants: real world experience

被引:0
作者
Petra Šinigoj
Nina Vene
Katarina Košmelj
Alenka Mavri
机构
[1] University Medical Centre Ljubljana,Department of Vascular Diseases
[2] University of Ljubljana,Department of Agronomy, Biotechnical Faculty
来源
International Journal of Clinical Pharmacy | 2020年 / 42卷
关键词
Atrial fibrillation; Direct oral anticoagulants; Elderly; Major bleeding; Oldest old;
D O I
暂无
中图分类号
学科分类号
摘要
Background The efficacy and safety of direct oral anticoagulants is well established in patients with atrial fibrillation. However, data on their use in the oldest old patients (≥ 85 years), who have the highest risk of bleeding, is scarce. Objective The aim of this study was to evaluate the safety of direct oral anticoagulants in the oldest old patients with atrial fibrillation and assess the impact of age on major bleeding events. Setting Anticoagulation Clinic of the Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia. Methods From our single-centre prospective registry we enrolled 2260 consecutive atrial fibrillation patients aged ≥ 65 years that were started on dabigatran, rivaroxaban or apixaban. The mean duration of treatment exposure was 735 days. The primary outcome was the incidence of major bleeding. The incidence of thromboembolic events and death were also assessed. Potential risk factors for major bleeding were evaluated using Cox regression analysis. Main outcome measure Rate of major bleeding. Results During the follow-up 106 patients experienced major bleeding (2.3%/year). The oldest old patients (≥ 85 years) had the highest risk of any major bleeding (HR 2.50, 95% CI 1.44–4.32, p = 0.001), intracranial bleeding (HR 4.74, 95% CI 1.48–15.14, p < 0.01) and major gastrointestinal bleeding (HR 2.32, 95% CI 1.10–4.89, p < 0.03) compared to the group of patients aged 65–74 years, even though the majority of them were treated with reduced doses of direct oral anticoagulants. Significant predictors for major bleeding were age group ≥ 85 years (HR 2.52, 95% CI 1.43–4.47, p = 0.001) and history of bleeding (HR 3.32, 95% CI 1.87–5.90, p < 0.001). The incidence of a composite of stroke, transient ischemic attack and systemic embolism was 1.3%/year. Conclusion In this prospective real-world clinical study we have shown that the oldest old patients have the highest risk of major bleeding, which is further increased with a patient’s history of bleeding.
引用
收藏
页码:445 / 452
页数:7
相关论文
共 157 条
[1]  
Wolf PA(1991)Atrial fibrillation as an independent risk factor for stroke: the framingham study Stroke 22 983-988
[2]  
Abbott RD(2013)Atrial fibrillation, stroke risk, and warfarin therapy revisited Stroke 44 3103-3108
[3]  
Kannel WB(2015)Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation J Am Heart Assoc 4 e001486-3335
[4]  
Björck S(2009)Age disparities in stroke quality of care and delivery of health services Stroke 40 3328-2962
[5]  
Palaszewski B(2016)2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur Heart J 37 2893-314
[6]  
Friberg L(2017)Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation Heart 103 307-2372
[7]  
Bergfeldt L(2016)Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011–2015 in Denmark Sci Rep 6 31477-146
[8]  
Haim M(2011)Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation Circulation 123 2363-1872
[9]  
Hoshen M(2014)Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism Circulation 130 138-681
[10]  
Reges O(2014)Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the Aristotle trial Eur Heart J 35 1864-1236